Ultra-high field imaging, plasma markers and autopsy data uncover a specific rostral locus coeruleus vulnerability to hyperphosphorylated tau
Year: 2023
Type: article
Study design: Observational Study
Abstract: Autopsy data indicate that the locus coeruleus (LC) is one of the first sites in the brain to accumulate hyperphosphorylated tau pathology, with the rostral part possibly being more vulnerable in the earlier stages of the disease. Taking advantage of recent developments in ultra-high field (7 T) imaging, we investigated whether imaging measures of the LC also reveal a specific anatomic correlation with tau using novel plasma biomarkers of different species of hyperphosphorylated tau, how early in adulthood these associations can be detected and if are associated with worse cognitive performance. To validate the anatomic correlations, we tested if a rostro-caudal gradient in tau pathology is also detected at autopsy in data from the Rush Memory and Aging Project (MAP). We found that higher plasma measures of phosphorylated tau, in particular ptau231, correlated negatively with dorso-rostral LC integrity, whereas correlations for neurodegenerative plasma markers (neurofilament light, total tau) were scattered throughout the LC including middle to caudal sections. In contrast, the plasma Aβ42/40 ratio, associated with brain amyloidosis, did not correlate with LC integrity. These findings were specific to the rostral LC and not observed when using the entire LC or the hippocampus. Furthermore, in the MAP data, we observed higher rostral than caudal tangle density in the LC, independent of the disease stage. The in vivo LC-phosphorylated tau correlations became significant from midlife, with the earliest effect for ptau231, starting at about age 55. Finally, interactions between lower rostral LC integrity and higher ptau231 concentrations predicted lower cognitive performance. Together, these findings demonstrate a specific rostral vulnerability to early phosphorylated tau species that can be detected with dedicated magnetic resonance imaging measures, highlighting the promise of LC imaging as an early marker of AD-related processes.
Source: Molecular Psychiatry
Institutions: Harvard University, Maastricht University, Gordon Center for Medical Imaging, Massachusetts General Hospital, King's College London, South London and Maudsley NHS Foundation Trust, Stavanger University Hospital, University of Gothenburg, Lund University, Brigham and Women's Hospital, Rush University Medical Center, Sahlgrenska University Hospital, Skåne University Hospital, UK Dementia Research Institute, National Hospital for Neurology and Neurosurgery, UCL Queen Square Institute of Neurology, University College London
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,990
Funders: Alzheimer's Association, Alzheimer's Drug Discovery Foundation, BrightFocus Foundation, Familjen Erling-Perssons Stiftelse, Cure Alzheimer's Fund, Stiftelsen för Gamla Tjänarinnor, EU Joint Programme – Neurodegenerative Disease Research, Australian Government, European Commission, Lunds Universitet, Hjärnfonden, Knut och Alice Wallenbergs Stiftelse, Vetenskapsrådet, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Alzheimer Nederland, Skånes universitetssjukhus, Marcus och Amalia Wallenbergs minnesfond, Universitätsklinikum Köln, UK Dementia Research Institute, Olav Thon Stiftelsen, National Institutes of Health, Parkinsonfonden, National Institute on Aging, H2020 European Research Council
Awards: G1057200632, G106931528, G1088883541, G1135383168, G1222782219, G1253720191, G1311708188, G1373393710, G1442296065, G1457535256, G1488855273, G150733400, G1551449788, G1588116593, G1802301745, G1833008592, Understanding Alzheimer Blood Biomarkers for Tau Pathology, G201353144, G2037823205, G2057385626, G2108271864, G237833635, G2385484910, G2543812357, Elevated locus coeruleus metabolism as mechanism driving Alzheimer's disease pathology, The effects of iron on oxidative stress and Alzheimer's biomarkers in amyloid-positive and negative elderly normal, G2799940023, The Alzheimer biomarker toolbox – use in pathogenic studies, diagnostics and theragnostics, G2841269746, G2879339865, G292763017, Development of new biomarkers and brain imaging techniques for Dementia and Parkinsonian disorders: key tools for exploring etiology to improve diagnosis and advance drug development, G3027168043, G308275008, G3126964432, G313301595, G3241251457, G3480186095, G3743240706, G3903502641, G3914690605, G4028979961, G4181470480, G4234328627, G4260843567, G432431387, G434337789, G4404751248, G5040492720, G506008078, G5111822078, G5166548482, G516766298, G5184609404, G5332654608, G5585422332, G5619075, G5619554209, G56684467, G5749088205, G581591135, G6066643948, G6142763750, G6168044258, G6289970089, Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis, Immunogenetic contribution to the progression of preclinical Alzheimer's disease, G670286326, G691317373, Pathways to Alzheimer's disease, G712881263, G7143958211, G728140114, G7359408231, 3rd International Conference on Tomography of Materials and Structures, G791739130, What determines amyloid beta aggregation and toxicity in Alzheimer’s disease?, G9000015626, G9000150306, G9000244657, The wandering nerve: gateway to boost Alzheimer's disease related cognitive performance, G958583170, G983864884
OpenAlex ID: W4362614482
